Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 12/20 | 0.39 |
| ▸ | CPB1 | P15086 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14790043 | 0.86 | CPB2 (0.38) | CPB2CPB1 | |
| SCHEMBL14551467 | 0.86 | CPB2 (0.40) | CPB2CPB1KDM4EALDH1A1MEN1 | |
| SCHEMBL14481389 | 0.84 | CPB2 (0.44) | CPB2CPB1 | |
| SCHEMBL10137877 | 0.84 | CPB2 (0.52) | CPB2CPB1KDM4EALDH1A1USP2 | |
| SCHEMBL31006001 | 0.79 | KDM4E (0.37) | CPB2CPB1KDM4EALDH1A1MEN1 | |
| SCHEMBL13563916 | 0.77 | CYP2C9 (0.46) | KDM4EALDH1A1MEN1KMT2AUSP2 | |
| SCHEMBL8865798 | 0.73 | CDK5 (0.54) | CPB2KDM4EALDH1A1KMT2A | |
| SCHEMBL8865591 | 0.72 | CDK5 (0.42) | ALDH1A1USP2 | |
| SCHEMBL18098599 | 0.72 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2AUSP2 | |
| SCHEMBL10274452 | 0.72 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2548872-B1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2548872-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | CPB2 13/4885CPB1 8/4885KDM4E 3778/4885 |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | CPB2 13/4885CPB1 8/4885KDM4E 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.